Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gottfredsson

Showing results (81-90 of 102) with videos related to

Pageof 11
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|January 25, 2008
Lessons from the past: familial aggregation analysis of fatal pandemic influenza (Spanish flu) in Iceland in 1918Magnús Gottfredsson, Bjarni V Halldórsson, Stefán Jónsson, et al.
Journal of Internal Medicine|March 8, 2018
Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agentsS Olafsson, T Tyrfingsson, V Runarsdottir, et al.
The International Journal on Drug Policy|October 25, 2024
Predictors of treatment outcomes for Hepatitis C infection in a nationwide elimination program in Iceland: The treatment as prevention for Hepatitis C (TraP HepC) studySigurdur Olafsson, Thorvardur Jon Love, Ragnheidur Hulda Fridriksdottir, et al.
The Lancet. Gastroenterology & Hepatology|June 25, 2021
Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) programme in Iceland: a population-based studySigurdur Olafsson, Ragnheidur H Fridriksdottir, Thorvardur J Love, et al.
HIV Medicine|October 7, 2017
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimensA Cozzi-Lepri, R Zangerle, L Machala, et al.
AIDS (London, England)|October 6, 2018
Variation in antiretroviral treatment coverage and virological suppression among three HIV key populationsKamilla Grønborg Laut, Leah Shepherd, Magnus Gottfredsson, et al.
HIV Medicine|August 8, 2022
Use of contraindicated antiretroviral drugs in people with HIV/HCV coinfections receiving HCV treatment with direct-acting antivirals-Results from the EuroSIDA studyMyroslava Nikolaichuk, Amanda Mocroft, Gilles Wandeler, et al.
Antiviral Therapy|January 6, 2018
Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA studyLars Peters, Amanda Mocroft, Daniel Grint, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 25, 2019
Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugsNed H Latham, Joseph S Doyle, Anna Y Palmer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2021
Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European CohortAnnegret Pelchen-Matthews, Álvaro H Borges, Joanne Reekie, et al.
Pageof 11

Showing results (81-90 of 102) with videos related to

Sort By:
Pageof 11
Proceedings of the National Academy of Sciences of the United States of America|January 25, 2008
Lessons from the past: familial aggregation analysis of fatal pandemic influenza (Spanish flu) in Iceland in 1918Magnús Gottfredsson, Bjarni V Halldórsson, Stefán Jónsson, et al.
Journal of Internal Medicine|March 8, 2018
Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agentsS Olafsson, T Tyrfingsson, V Runarsdottir, et al.
The International Journal on Drug Policy|October 25, 2024
Predictors of treatment outcomes for Hepatitis C infection in a nationwide elimination program in Iceland: The treatment as prevention for Hepatitis C (TraP HepC) studySigurdur Olafsson, Thorvardur Jon Love, Ragnheidur Hulda Fridriksdottir, et al.
The Lancet. Gastroenterology & Hepatology|June 25, 2021
Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) programme in Iceland: a population-based studySigurdur Olafsson, Ragnheidur H Fridriksdottir, Thorvardur J Love, et al.
HIV Medicine|October 7, 2017
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimensA Cozzi-Lepri, R Zangerle, L Machala, et al.
AIDS (London, England)|October 6, 2018
Variation in antiretroviral treatment coverage and virological suppression among three HIV key populationsKamilla Grønborg Laut, Leah Shepherd, Magnus Gottfredsson, et al.
HIV Medicine|August 8, 2022
Use of contraindicated antiretroviral drugs in people with HIV/HCV coinfections receiving HCV treatment with direct-acting antivirals-Results from the EuroSIDA studyMyroslava Nikolaichuk, Amanda Mocroft, Gilles Wandeler, et al.
Antiviral Therapy|January 6, 2018
Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA studyLars Peters, Amanda Mocroft, Daniel Grint, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 25, 2019
Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugsNed H Latham, Joseph S Doyle, Anna Y Palmer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2021
Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European CohortAnnegret Pelchen-Matthews, Álvaro H Borges, Joanne Reekie, et al.
Pageof 11